1 =============================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ----------------- FORM 8-K CURRENT REPORT, PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (Date of Earliest Event Reported): June 18, 1997 (June 13, 1997) NU-TECH BIO-MED, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-11772 25-1411971 - ---------------------------- ------------------------ ------------------- (State or Other Jurisdiction (Commission File Number) (I.R.S. Employer of Incorporation Identification No.) 55 Access Road Warwick, Rhode Island 02886 --------------------- ----- (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (401) 732-6520 ----------------- =============================================================================== 2 ITEM 5. OTHER EVENTS. On April 29, 1997, Nu-Tech Bio-Med, Inc. (the "Company") reduced the exercise price of 1,076,979 warrants (the "Warrants") and 15,856 options (the "Options"), respectively, to $1.76 per share, which price is equal to 75% of the average closing price for the Company's common stock for the ten (10) days prior to such reduction. Such reduction was effected for a 45 day period through June 13, 1997. As of June 13, 1997, the Company received an aggregate of approximately $619,000 as a result of the exercise of 351,728 options/ warrants. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. NU-TECH BIO-MED, INC. By: /s/ J. Marvin Feigenbaum ------------------------------- Name: J. Marvin Feigenbaum Title: Chairman of the Board, President, Chief Executive and Chief Financial Officer Date: June 18, 1997 2